DP
EWTX icon

Diadema Partners’s Edgewise Therapeutics EWTX Stock Holding History

Diadema Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.69M Buy
+212,500
New +$6.13M 1.14% 31
2025
Q2 		– Sell
-98,200
Closed -$2.16M – 110
2025
Q1 		$2.16M Buy
+98,200
New +$2.58M 0.56% 42

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Diadema Partners's EWTX Position: Q1 2026 in Review

Diadema Partners sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 30,000 shares — an estimated $865K sold.

Diadema Partners first reported a position in EWTX in Q4 2024 and held it in 2 quarters. The position peaked at $744K in Q4 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Diadema Partners reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Diadema Partners sold 30,000 Edgewise Therapeutics shares in Q1 2026, an estimated $865K.
  • Diadema Partners first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 2 quarters.
  • Diadema Partners's Edgewise Therapeutics position peaked at $744K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.